Trials that use: Confidence intervals
New to this method? Read the tutorial →
407 results
- SPRING-2Independent statistical analysis of the SPRING-2 phase 3 trial comparing dolutegravir 50 mg once daily with raltegravir 400 mg twice daily for HIV-1 infection, including its non-inferiority design, stratified Cochran-Mantel-Haenszel analysis, confidence…
- STARSCAPEIndependent statistical analysis of the STARSCAPE phase 3 trial of zinpentraxin alfa in idiopathic pulmonary fibrosis, including trial design, endpoints, randomized efficacy analysis, time-to-event methods, safety, limitations, and statistical interpretation.
- STELLARIndependent statistical analysis of the phase 3 STELLAR trial of sotatercept plus background PAH therapy versus placebo plus background PAH therapy in pulmonary arterial hypertension, including trial design, endpoints, nonparametric analyses, hazard…
- STEP 1Complete statistical analysis of STEP 1 (NCT03548935), a randomized phase 3 trial of semaglutide 2.4 mg versus placebo in people with overweight or obesity, including its ANCOVA and logistic-regression analyses, effect estimates,…
- STEP 2Complete statistical analysis of STEP 2, the randomized phase 3 trial of semaglutide in people with type 2 diabetes and overweight or obesity, including trial design, primary endpoints, ANCOVA, MMRM, logistic regression,…
- STEP 3Complete statistical analysis of STEP 3 (NCT03611582), a phase 3 randomized trial evaluating semaglutide versus placebo for weight reduction in people with overweight or obesity, including endpoint definitions, ANCOVA, MMRM, logistic regression,…
- STEP 4Independent statistical analysis of STEP 4 (NCT03548987), a randomized phase 3 trial evaluating change in body weight with semaglutide 2.4 mg versus placebo in people with overweight or obesity.
- STEP 5Complete statistical analysis of the STEP 5 phase 3 trial of semaglutide versus placebo in adults with overweight or obesity, including trial design, primary endpoints, ANCOVA, MMRM, logistic regression, confidence intervals, and…
- STEP 8Complete statistical analysis of STEP 8, a randomized phase 3 trial comparing semaglutide 2.4 mg with liraglutide 3.0 mg in people living with overweight or obesity, including the registered body-weight endpoint, ANCOVA…
- STEP-HFpEFIndependent statistical analysis of the phase 3 STEP-HFpEF trial of semaglutide in people living with heart failure and obesity, including trial design, ANCOVA methodology, primary endpoints, confidence intervals, p-values, safety, and interpretation.
- STRENGTHComplete statistical analysis of the STRENGTH phase 3 trial of Epanova versus corn oil control in high cardiovascular risk patients with hypertriglyceridemia, including trial design, MACE, Cox proportional-hazards analysis, secondary endpoints, safety,…
- STRIVEComplete statistical analysis of the STRIVE phase 3 trial of erenumab for migraine prevention, including randomized trial design, primary and secondary endpoint analyses, mixed-effects models, Cochran-Mantel-Haenszel testing, multiplicity, and safety.
- STROKE-AFIndependent statistical analysis of STROKE-AF (NCT02700945), a randomized trial evaluating atrial fibrillation detection through 12 months with Reveal LINQ insertable cardiac monitoring after recent ischemic stroke of presumed known origin.
- SUNLIGHTIndependent statistical analysis of the phase 3 SUNLIGHT trial of trifluridine/tipiracil with and without bevacizumab in refractory metastatic colorectal cancer, including trial design, time-to-event endpoints, hazard ratios, confidence intervals, and statistical interpretation.
- SURMOUNT-3Independent statistical analysis of the phase 3 SURMOUNT-3 trial of tirzepatide in participants with obesity or overweight after a lifestyle weight loss program, including trial design, primary endpoints, reported estimates, statistical methods,…
- SURMOUNT-OSAIndependent statistical analysis of SURMOUNT-OSA, a randomized phase 3 trial of tirzepatide in participants with obstructive sleep apnea and obesity, including AHI results, ANCOVA, logistic regression, confidence intervals, and safety.
- SURPASS-3Complete statistical analysis of SURPASS-3, a randomized phase 3 trial comparing tirzepatide with insulin degludec in participants with type 2 diabetes, including HbA1c, body weight, fasting serum glucose, treatment satisfaction, statistical methodology,…
- SURPASS-4Independent statistical analysis of SURPASS-4, a randomized phase 3 trial of once-weekly tirzepatide versus once-daily insulin glargine in participants with type 2 diabetes and increased cardiovascular risk.
- SURPASS-5Complete statistical analysis of SURPASS-5, a randomized phase 3 trial of tirzepatide versus placebo in participants with type 2 diabetes inadequately controlled on insulin glargine with or without metformin.
- SUSTAIN-3Independent statistical analysis of SUSTAIN-3, the randomized phase 3 trial comparing once-weekly semaglutide 1.0 mg with exenatide ER 2.0 mg in subjects with type 2 diabetes receiving 1–2 oral antidiabetic drugs.
- SUSTAIN-7Independent statistical analysis of the SUSTAIN-7 phase 3 trial comparing semaglutide with dulaglutide as add-on to metformin in subjects with type 2 diabetes, including mixed-effects modeling, non-inferiority and superiority testing, confidence intervals,…
- SWITCH 1Independent statistical analysis of SWITCH 1 (NCT02034513), a randomized double-blind phase 3 crossover trial comparing insulin degludec with insulin glargine in type 1 diabetes, including its non-inferiority framework, Poisson regression, MMRM, McNemar…
- SWITCH 2Independent statistical analysis of SWITCH 2, a randomized double-blind crossover phase 3 trial comparing insulin degludec with insulin glargine in subjects with type 2 diabetes, including hypoglycaemia, HbA1c, crossover design, non-inferiority, and…
- SWOG 9346Independent statistical analysis of SWOG 9346, a randomized phase 3 trial of intermittent versus continuous hormonal therapy in men with stage IV prostate cancer, including overall survival and 3-month functional outcomes.
- SWOG S0777Independent statistical analysis of SWOG S0777 (NCT00644228), a randomized phase 3 trial of lenalidomide and dexamethasone with or without bortezomib in previously untreated multiple myeloma.
- TAILORxIndependent statistical analysis of the TAILORx phase 3 trial, focusing on 5-year disease-free survival, the Cox proportional-hazards model, hazard ratios, confidence intervals, and the trial's noninferiority design.
- TALAPRO-2Independent statistical analysis of TALAPRO-2, evaluating talazoparib plus enzalutamide versus placebo plus enzalutamide in mCRPC, with detailed interpretation of radiographic progression-free survival and the trial's survival-analysis methods.
- TBTC Study 31Complete statistical analysis of TBTC Study 31, a randomized phase 3 trial of rifapentine-containing tuberculosis treatment-shortening regimens, including non-inferiority methodology, disease-free survival, safety, confidence intervals, and interpretation.
- TDF2Independent statistical analysis of the randomized TDF2 trial of tenofovir disoproxil fumarate plus emtricitabine for HIV prevention, including trial design, registered endpoints, Cox and logistic regression methods, reported results, safety, limitations, and…
- TEAMIndependent statistical analysis of TEAM, the randomized phase 3 trial comparing exemestane with tamoxifen followed by exemestane in postmenopausal patients with receptor-positive breast cancer. Includes disease-free survival, overall survival, time to relapse,…
- TECOSComplete statistical analysis of TECOS, the randomized phase 3 study of sitagliptin versus placebo in type 2 diabetes mellitus, including non-inferiority analysis of MACE plus, Cox proportional-hazards methodology, secondary endpoints, safety, and…
- TEXTIndependent statistical analysis of TEXT, a randomized phase 3 trial of triptorelin with either exemestane or tamoxifen in premenopausal women with hormone-responsive breast cancer, including time-to-event endpoints, hazard ratios, confidence intervals, log-rank…
- TH3RESAIndependent statistical analysis of TH3RESA, a randomized phase 3 trial of trastuzumab emtansine versus treatment of physician's choice in participants with HER2-positive breast cancer who had received at least two prior HER2-directed…
- THALESComplete statistical analysis of the phase 3 THALES trial of ticagrelor versus placebo in acute ischaemic stroke and transient ischaemic attack, including trial design, endpoints, Cox and logistic regression methods, efficacy results,…
- THEMISIndependent statistical analysis of THEMIS, a randomized phase 3 trial of ticagrelor 60 mg versus placebo in patients with type 2 diabetes mellitus, including time-to-event methods, hazard ratios, confidence intervals, safety analyses,…
- THORComplete statistical analysis of the phase 3 THOR trial of erdafitinib in participants with advanced urothelial cancer and selected FGFR gene aberrations, including overall survival, trial design, statistical methodology, and interpretation.
- TITANIndependent statistical analysis of TITAN (NCT02489318), a randomized phase 3 trial of apalutamide plus androgen deprivation therapy versus androgen deprivation therapy in participants with metastatic hormone-sensitive prostate cancer.
- ToGAIndependent statistical analysis of the ToGA phase 3 trial of trastuzumab plus fluoropyrimidine/cisplatin versus fluoropyrimidine/cisplatin alone in patients with HER2-positive advanced gastric cancer, including survival, response, statistical methods, interpretation, and safety.
- TOPAZ-1Independent statistical analysis of TOPAZ-1, evaluating durvalumab plus gemcitabine/cisplatin versus placebo plus gemcitabine/cisplatin in advanced biliary tract cancer, including survival endpoints, response, statistical methods, and interpretation.
- TRA 2P-TIMI 50Independent statistical analysis of TRA 2P-TIMI 50 (NCT00526474), including randomized trial design, time-to-event endpoints, Cox proportional-hazards methods, efficacy results, bleeding outcomes, post-hoc analyses, and statistical interpretation.
- TRAILBLAZER-ALZ 2A detailed statistical analysis of TRAILBLAZER-ALZ 2, a randomized phase 3 study of donanemab versus placebo in participants with early Alzheimer's disease, including endpoint results, mixed-effects models, ANCOVA, confidence intervals, and interpretation.
- TRANSITIONIndependent statistical analysis of the TRANSITION phase 4 trial comparing pre- and post-discharge initiation of LCZ696 in patients with heart failure with reduced ejection fraction after an acute decompensation event.
- TRITON3Independent statistical analysis of TRITON3, a randomized phase 3 trial of rucaparib versus physician's choice of therapy in metastatic castration-resistant prostate cancer with BRCA or ATM alterations.
- TROPiCS-02Independent statistical analysis of TROPiCS-02, a randomized phase 3 trial of sacituzumab govitecan-hziy versus treatment of physician's choice in participants with HR+/HER2- metastatic breast cancer.
- TROPiCS-04Independent statistical analysis of TROPiCS-04, a randomized phase 3 trial of sacituzumab govitecan versus physician's choice of treatment in locally advanced or metastatic unresectable urothelial cancer.
- TROPION-Breast01Independent statistical analysis of TROPION-Breast01, evaluating Dato-DXd versus investigator's choice of chemotherapy in participants with inoperable or metastatic HR-positive, HER2-negative breast cancer.
- TULIPIndependent statistical analysis of the phase 3 TULIP trial of (vic-)trastuzumab duocarmazine versus physician's choice in participants with HER2-positive locally advanced or metastatic breast cancer, including progression-free survival, overall survival, response, quality…
- VADTIndependent statistical analysis of VADT (NCT00032487), evaluating intensive versus standard glycemic control in type 2 diabetes, with a focus on major macrovascular events, hazard ratios, log-rank testing, confidence intervals, and equivalence testing.
- VELIAIndependent statistical analysis of the VELIA phase 3 trial of veliparib with carboplatin and paclitaxel and as continuation maintenance therapy in adults with newly diagnosed stage III or IV high-grade serous epithelial…
- VELOURIndependent statistical analysis of the phase 3 VELOUR trial of aflibercept plus FOLFIRI versus placebo plus FOLFIRI in metastatic colorectal cancer after failure of an oxaliplatin-based regimen, including trial design, survival analysis,…